Baby lizard hatched at British zoo after extremely rare ‘virgin birth'
Izzy the eastern casquehead iguana was conceived with no male involvement.
She hatched from one of two marble-sized eggs laid by five-year-old female Alma, which went through parthenogenesis — a form of reproduction when an embryo develops from an unfertilised egg.
The process, which happens in fewer than one in 1,000 vertebrate births, sees the body find a way of filling in for genes usually provided by sperm.
Izzy, whose species is native to Central and South America, was born on Sunday at Battersea Park Children's Zoo in South West London.
Manager Jamie Baker, 30, said: 'We were amazed.
"We've no male eastern casquehead iguanas so when we discovered one of our females had laid eggs, it was exciting.
'We didn't think they'd hatch but decided to incubate them anyway as we were aware that the species have been known to reproduce via parthenogenesis.'
He said Izzy, a genetic clone of her mum, was about the size of an adult little finger.
He said: 'She's growing well.
"She's in her nursery enclosure feeding on fruit flies and tiny crickets.
'We're keeping her on her own because if we left her in with the adults they'd eat her.
Moment iguana casually crawls onto tennis court before worker is forced to shoo it away
"They're not an animal that gives parental care.
'Our priority is to get Izzy to a good enough size so that she can move in with the adults.'
1
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
21 hours ago
- BBC News
Next generation of cancer drugs could be made in space
Many companies are racing towards the space economy, a commercial sector projected to reach 1.8 trillion US dollars in the next decade. We're already turning to the stars for holidays with tour operators, farming, and one day soon the atmospheric conditions of space. Tech Now visits a London based startup aiming to improve disease treatment by building a pharmaceutical factory in space. This video is from Tech Now, the BBC's flagship technology programme.
Daily Mail
21 hours ago
- Daily Mail
Student with higher IQ than Stephen Hawking gets 23 A-levels (After her school questioned her over her attendance record!)
A student with a higher IQ than Stephen Hawking has achieved a staggering 23 A-levels with grades of A and A*. Mahnoor Cheema, has an IQ of 161 - one point higher than the famous theoretical physicist. The diligent student received an unconditional offer to study medicine at the University of Oxford following her impressive results, fulfilling her childhood dream. But it wasn't plain-sailing for the London teen who was questioned over her attendance record by her school and almost blocked from sitting her exams after missing lessons to take the necessary tests. Mahnoor, who attended Henrietta Barnett School (HBS) in north-west London, was challenged by staff over her desire to study 31 A Levels. Most pupils across England and Wales achieve just three A Level and the high-performing school objected to the star-pupil's plans. As a compromise she and the school agreed to just 23 - more than seven times the average. And it was a mammoth task for Mahnoor who secured four A* in her first two months at the sixth form. The teen sat exams in environmental management, marine science, English language and thinking skills. She previously said she has no regrets about the exams and would be 'bored and understimulated' if she only did the standard three A-levels - and said burnout is 'a choice'. 'I have loads of interests, that's why I wanted to do so many subjects - it doesn't take that much time or effort. 'I think if you have the capability to do more, it should be explored - I would be bored doing only three subjects over two years. 'Burnout is a big thing for some people but I'm just motivated and driven and it doesn't affect me. She added: 'I see burnout as a choice - it's not burnout if you enjoy what you're doing.' Mahnoor, who studied 24 GCSEs in her own time alongside 10 at Langley Grammar School and scored 33 nines and one eight - equivalent to 33 A*s and one A/A*, was supported by her mother Tayyaba, as she studied from home and her hard work has certainly paid off. On Tuesday she learnt she had achieved A*s in Law and History and on A Level results day on Thursday, she found out the last of her results which included a further two qualifications in French and Physics. In total the teen studied psychology, sociology, law, business, accounting, economics, Latin, German, computer science, film studies, politics, classical civilisation, maths, further maths, geography and media studies, physics, chemistry, biology, English literature, film studies, French, statistics and accounting. The grammar school pupil, from Slough, Berkshire, had already received an unconditional offer from Exeter College, Oxford, in January having achieved the science A-levels needed earlier in the year. And while it may have been a difficult slog, the talented pupil was sure she would achieve her dream. 'I was absolutely set on it [studying medicine at Oxford]. There was not a world in my mind where I would not get in. That is not cocky but that was my determined life path. If I did not get in I would have reapplied,' she told The Telegraph. Henrietta Barnett School is one of the best state schools for getting pupils into the prestigious universities of Oxford and Cambridge and according to recent data, it has an average of 34 offers per year meaning pupils have a 43 per cent success rate. Mahnoor was born in the UK before moving to Lahore, Pakistan with her parents in 2010. Her family then moved back to the UK in 2016 and her mother Tayyaba Cheema, 43, a full-time mum with a masters in Economics, said Mahnoor was 'quite different' from a young age. By the age of six, Mahnoor had read all seven Harry Potter books, and by 11 had learned the entire Oxford English Dictionary 'by heart'. Mahnoor was one of thousands of pupils across the UK who excitedly open their results and was one of just 28.3 per cent of pupils got A/A* this year, compared with 27.8 per cent last year, and 25.4 per cent in 2019. And she is not the only success story. At Brampton Manor in East Ham, more than half of all pupils achieved a full set of A* or A grades, with dozens of pupils securing places at universities such as Oxford, Cambridge, Imperial and UCL. The school is the world's top school for Oxbridge entry, having sent 85 pupils to the prestigious universities in 2022, up from 57 in 2021 and 53 in 2020.
BBC News
a day ago
- BBC News
RDEB trial gives hope to children suffering from painful skin condition
A boy with a rare and painful skin condition has been given hope after taking part in a trial for a potential treatment for the genetic Misurenkovas, 12, from east London, was diagnosed with the inflammatory disease recessive dystrophic epidermolysis bullosa (RDEB) when he was a rare genetic disease is severely debilitating and even the smallest amount of friction can cause damage and lead to blistering, deep wounds and the trial, Gabrielius received certain stem cells via an intravenous drip to help alleviate the painful condition. About 150 children in the UK are affected by no disease-modifying treatment available, patients and their families usually manage symptoms by dressing wounds and applying eye time, the condition can lead to severe complications and patients can develop a type of skin cancer called squamous cell carcinoma when they are young adults - this is the most common cause of death for RDEB patients, according to has been under the care of medics at children's hospital Great Ormond Street (GOSH) since he was a said he jumped at the chance to join the clinical trial when it was suggested by his doctors."I wanted to take part in the trial as I was excited to see if it could help improve my condition and so I could do more of the things I enjoy, like playing football and spending time with my friends," he the youngster, who can speak three languages and is a big fan of footballer Lionel Messi, needed his bandages changing three times a day or more if he was injured. His mother, Jolita Cekaviciene, said: "Gabrielius did really well on the trial."His wounds healed quicker, and his skin was less red and inflamed."His skin was also less itchy which also reduced him scratching."His sleep was also less disturbed as he didn't need to have his special wound dressings changed as often, so this was a great benefit."She said Gabrielius had managed to do a few things that he was not able to before having the treatment, including taking part in some sports at school, riding his bike in the park on the grass, and being able to play football with his friends, using a soft Cekaviciene said the trial had given her son more freedom than before, but he still needed to be careful in any activity to avoid falling over or was referred to GOSH as a baby after medics spotted a wound when he was born, and he was diagnosed with RDEB when he was two weeks Cekaviciene said: "The first two years were really hard as you had to watch him constantly - even rubbing his eyes could cause painful blistering."He couldn't even tell us how much pain he was in or where he was hurting." RDEB is a genetic condition caused by a fault in the gene that makes a protein which holds layers of skin together - collagen wanted to assess whether regular infusions with mesenchymal stromal cells (MSC) improved symptoms for children with the condition, after studies suggested that such treatments could promote wound healing, reduce inflammation and stimulate tissue is one of 30 children who took part in the new clinical trial at GOSH and Birmingham Children's Hospital, which was funded by NHS England, the National Institute for Health and Care Research and the charity Cure it patients would go into hospital and have a drip which delivered the cells as an infusion over 10 to 15 minutes. The study, published in the journal eClinicalMedicine, reported a positive outcome of the largest effects were in children under the age of 10, and in the children with an intermediate type of involved in the study reported a positive impact on daily life and well-being, with a reduction in both pain and treatment was said to have been well tolerated by the the firm behind the treatment, has agreed to provide it free of charge for a year for all children who took part in the trial, so researchers can continue to study them, and patients are expected to get two infusions of the treatment every four company is seeking regulatory approval for the treatment so it can be approved for use in the UK and other countries.
